Curated News
By: NewsRamp Editorial Staff
October 13, 2026
New Tumor-Suppressive Circuit Offers Hope for Liver Cancer Treatment
TLDR
- Okayama University researchers defined a SPRED2/p53/miR-506-3p/KLF4 axis, offering a first-mover advantage for therapies targeting HCC stemness and chemoresistance.
- SPRED2 binds p53, enters the nucleus, and activates miR-506-3p, which directly targets KLF4 mRNA to reduce cancer stem cell traits in HCC.
- This discovery offers hope for liver cancer patients by potentially reducing relapse and metastasis through a newly identified tumor-suppressive pathway.
- The study reveals how a protein called SPRED2 teams up with p53 to suppress liver cancer stem cells via a microRNA, suggesting new treatment targets.
Impact - Why it Matters
This discovery matters because hepatocellular carcinoma is the second leading cause of cancer death worldwide, with high recurrence rates and limited treatment options. Cancer stem cells drive relapse, metastasis, and chemotherapy resistance, making them a critical target. By identifying the SPRED2/p53/miR-506-3p/KLF4 axis, researchers have provided a new therapeutic target that could lead to innovative treatments to suppress HCC stemness and improve patient outcomes. The findings also highlight the importance of p53 status in determining treatment response, paving the way for personalized medicine approaches. Ultimately, this research could lead to therapies that reduce relapse and extend survival for liver cancer patients.
Summary
Researchers at Okayama University in Japan have uncovered a novel tumor-suppressive circuit that controls stem-like behavior in hepatocellular carcinoma (HCC), the most common form of primary liver cancer. The study, published (DOI: 10.20892/j.issn.2095-3941.2025.0247) in Cancer Biology & Medicine, identifies a signaling axis involving SPRED2, p53, miR-506-3p, and KLF4 that regulates cancer stem cell (CSC) traits. The team found that SPRED2 binds to the tumor suppressor p53, enters the nucleus, and activates transcription of the microRNA miR-506-3p. This microRNA then directly targets KLF4 messenger RNA, reducing KLF4 protein levels and thereby decreasing CSC characteristics such as sphere formation, colony growth, invasion, and aldehyde dehydrogenase (ALDH) activity.
Using HepG2, HLE, and Hep3B HCC cell lines, SPRED2-deficient and overexpressing cells, a mouse xenograft model, and 40 paired human HCC samples, the researchers combined multiple molecular techniques to map the pathway. They demonstrated that KLF4 is a key pluripotency factor driving stemness, and that its knockdown reduces CSC traits and tumor growth in mice. Mechanistically, miR-506-3p directly binds the 3′ untranslated region of KLF4 mRNA. In human HCC samples, KLF4 and miR-506-3p were negatively correlated, while SPRED2 and miR-506-3p were positively correlated. The study also revealed that SPRED2 forms a nuclear complex with p53, which supports SPRED2 nuclear localization and binds the miR-506 promoter. Additionally, ERK and STAT3 inhibition raised miR-506-3p levels, linking three signaling pathways to KLF4 suppression.
The authors conclude that this SPRED2/p53/miR-506-3p/KLF4 axis represents a previously unrecognized tumor-suppressive circuit that could be targeted therapeutically. Restoring this pathway might reduce HCC progression, recurrence, and treatment resistance, particularly in tumors with intact p53 signaling. Future research should focus on testing miR-506-3p mimics, SPRED2-stabilizing agents, or combination therapies in preclinical models to translate these findings into precision approaches for HCC patients.
Source Statement
This curated news summary relied on content distributed by 24-7 Press Release. Read the original source here, New Tumor-Suppressive Circuit Offers Hope for Liver Cancer Treatment
